<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="presence of proteins, enzymes, metallic ions, flavonoids, and presentment of" exact="ascorbic acid" post="preserve from sugars and oxidation (Rein, 2005). Figure 4"/>
 <result pre="cytokines and mediators including IL-1, IL-6, IL-10, TNF-a, NF-kB, inducible" exact="nitric oxide" post="synthase and COX-2)(Bowen-Forbes et al., 2010; Sodagari et al.,"/>
 <result pre="inhibitory activity against H274Y mutation. The inhibitory activity of C3S," exact="oseltamivir" post="and their mechanisms against H274Y mutant-type (MT) and wild-type"/>
 <result pre="this line, self-assembled nanoparticles were prepared by chitosan (CH) and" exact="chondroitin sulfate" post="(CS) biopolymers to enhance the biological activity of black"/>
 <result pre="nanocomplexes exhibited excellent stability against different temperature, different concentration of" exact="ascorbic acid," post="varying pH or white fluorescent light (Ge et al.,"/>
 <result pre="chitosan hydrochloride; CMC, carboxymethyl chitosan; β-Lg, β-Lactoglobulin; CH, chitosan; CS," exact="chondroitin sulfate;" post="PLGA, poly lactic-co-glycolic acid; PEG, polyethylene glycol. References References"/>
 <result pre="al. (2007). Safety and efficacy of the HIV-1 integrase inhibitor" exact="raltegravir" post="(MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase"/>
 <result pre="G.et al. (1997). Efficacy and safety of the neuraminidase inhibitor" exact="zanamivir" post="in the treatment of influenzavirus infections. N. Engl. J."/>
 <result pre="(2018). Effectiveness, safety, and costs of a treatment switch to" exact="dolutegravir" post="plus rilpivirine dual therapy in treatment-experienced HIV patients. Ann."/>
 <result pre="safety, and costs of a treatment switch to dolutegravir plus" exact="rilpivirine" post="dual therapy in treatment-experienced HIV patients. Ann. Pharmacother.52 (1),"/>
 <result pre="SorianoV.PernoC.-F.KaiserR.CalvezV.GatellJ. M.Di PerriG.et al. (2009). When and how to use" exact="maraviroc" post="in HIV-infected patients. Aids23 (18), 2377–2385. 10.1097/QAD.0b013e328332d32d19834318 SuX.D’SouzaD. H."/>
</results>
